Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...5051525354555657585960...143144»
  • ||||||||||  adagrasib (MRTX849) / Mirati, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Adagrasib Data Create Buzz at ESMO. (Pubmed Central) -  Oct 6, 2021   
    Among patients who received the drug combination, the disease control rate was 100%; data on progression-free survival were immature. The findings, along with data on the KRAS inhibitor sotorasib, were presented at the 2021 European Society for Medical Oncology Congress.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, LEAC-102 / Taiwan Bio
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) -  Oct 6, 2021   
    P1/2,  N=30, Not yet recruiting, 
    The findings, along with data on the KRAS inhibitor sotorasib, were presented at the 2021 European Society for Medical Oncology Congress. Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Feb 2022 --> Feb 2024
  • ||||||||||  feladilimab (GSK3359609) / GSK
    Trial completion, Trial completion date, Combination therapy, Metastases:  GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (clinicaltrials.gov) -  Oct 6, 2021   
    P1/2,  N=26, Completed, 
    When indicated, placement of hepatic arterial infusion pump can successfully and safely be performed at the time of combined colorectal and liver resection. Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Sep 2021
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Clinical, Journal:  Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine. (Pubmed Central) -  Oct 6, 2021   
    Sensitivity of PDX toward conventional and targeted drugs revealed that 92% of PDX responded toward irinotecan, 45% toward 5-FU, 65% toward bevacizumab, and 61% toward cetuximab...Proto-oncogene B-RAF, EGFR, Kirsten rat sarcoma virus oncogene homolog gene copy number correlated positively with cetuximab and erlotinib sensitivity...Global proteome and phosphoproteome profiling showed a reduction in canonical EGFR-mediated signaling via PTPN11 (SHP2) and AKT1S1 (PRAS40) and an increase in anti-apoptotic signaling as a consequence of acquired cetuximab resistance. This demonstrates that PDX models provide a multitude of possibilities to identify and validate biomarkers, signaling pathways and resistance mechanisms for clinically relevant improvement in cancer therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
    Journal:  Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer. (Pubmed Central) -  Oct 6, 2021   
    This demonstrates that PDX models provide a multitude of possibilities to identify and validate biomarkers, signaling pathways and resistance mechanisms for clinically relevant improvement in cancer therapy. No abstract available
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    [VIRTUAL] Overall survival (OS with encorafenib (enco + cetuximab (cetux in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC. () -  Oct 5, 2021 - Abstract #COSA2021COSA_184;    
    P3
    In the BEACON CRC study (NCT02928224, median OS (95% CI with the doublet was 9.3 months (8.0–11.3 vs 5.9 months (5.1–7.1 with cetux + irinotecan or FOLFIRI (control in patients (pts with BRAF V600E-mutant mCRC (HR 0.61 [95% CI: 0.5–0.8]...Methods : OS of pts treated with the doublet or control were compared according to prior treatment with bevacizumab, oxaliplatin, or FOLFOXIRI and duration of prior anticancer therapy (ACT...This exploratory post-hoc analysis provides data that reflect the prior treatment landscape clinicians may face when deciding subsequent treatment regimens for pts with BRAF V600E-mutant mCRC. Clinical trial information: NCT02928224.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, BCA101 / Biocon
    Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy (Poster Hall) -  Oct 1, 2021 - Abstract #SITC2021SITC_1158;    
    In PDX models derived from head and neck cancer squamous cell carcinoma patients, BCA101 exerted sustained antitumor effect and delayed tumor growth compared to cetuximab...Anti-PD1 antibody (pembrolizumab) was administered intraperitoneally at a dose of 10 mg/kg with a dosage schedule of every fifth-day for 5 doses (Q5Dx5)...Tumor volumes are presented as Mean ± SEM. Conclusions These results support the clinical development of BCA101 as a targeted immunotherapy with the potential to induce improved anti-tumor response with a wider therapeutic window, either as a monotherapy or in combination with immune checkpoint blockade therapy.
  • ||||||||||  SAR444245 / Sanofi, Proleukin (aldesleukin) / Clinigen, Novartis, Prometheus, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Pegasus GI, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with anti-cancer agents of participants with advanced and metastatic gastrointestinal cancer (Poster Hall) -  Oct 1, 2021 - Abstract #SITC2021SITC_947;    
    The Pegasus GI Ph 2 study will evaluate the clinical benefit of SAR444245 in combination with pembrolizumab or cetuximab for the treatment of participants with advanced or metastatic gastrointestinal cancer [esophageal squamous cell carcinoma (ESCC), gastric cancer (GC) or gastro-esophageal junction adenocarcinoma (GEJ), Hepatocellular carcinoma (HCC) or colorectal cancer (CRC)] Methods Pegasus GI will enroll approximately 280 patients in 7 separate cohorts concurrently (4 cohorts) or sequentially (3 cohorts). In cohort A, 2–3 line (L) ESCC participants who have progressed after checkpoint inhibitor (CPI)-based therapy will receive SAR444245 + pembrolizumab.
  • ||||||||||  CLEC-1 mAbs / OSE Immunotherapeutics, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Preclinical efficacy of CLEC-1 antagonist as novel myeloid immune checkpoint therapy for oncology (Poster Hall) -  Oct 1, 2021 - Abstract #SITC2021SITC_871;    
    Results Using newly developed anti-human CLEC-1 monoclonal antibodies (mAbs), we found that antagonist anti-CLEC-1 mAbs with the capacity to block CLEC-1/CLEC-1Ligand interaction, as opposed to non-antagonist CLEC-1 mAbs, increase the phagocytosis of CLEC-1Ligand-positive human tumor cells by human macrophages, in particular when opsonized by tumor-associated antigen mAbs (Rituximab, Cetuximab, Trastuzumab) or with anti-CD47 mAb (Magrolimab)...CLEC1 KO mice also illustrate significant eradication of MC38 colorectal tumors in combination with chemotherapy promoting CLEC-1Ligand expression by tumor cells (n=16 with Gemcitabine or n=11 with Cyclophosphamide)...Finally, we recently generated human CLEC-1 knock-in mice expressing the extracellular human CLEC1 domain fused to the intracellular mouse CLEC1 tail and confirmed preclinical efficacy in vivo with anti-human CLEC1 antagonist mAb in monotherapy in the orthotopic HCC model. Conclusions These data illustrate that CLEC-1 inhibition represents a novel therapeutic target for immuno-oncology modifying T cell immune responses and tumor cell phagocytosis by macrophages.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Functionalizing CAR T cells for selective proliferation and dual-targeting using the meditope technology (Poster Hall) -  Oct 1, 2021 - Abstract #SITC2021SITC_825;    
    Background Meditope is a small cyclic peptide that was identified to bind to cetuximab within the Fab region...For meCAR T cell proliferation and dual-targeting assays, the meditope peptide (meP) was conjugated to recombinant human IL15 fused to the CD215 sushi domain (meP-IL15:sushi) and anti-CD20 monoclonal antibody rituximab (meP-rituximab)...Further, meP-ritiuximab can redirect meCAR T cells to target CD20-tumors, showing the versatility of this platform to address the tumor antigen escape variants. Future studies are focused on conferring additional ‘add-on’ functionalities to meCAR T cells to potentiate the therapeutic effectiveness of CAR T cell therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Drug repurposing as a source of innovative therapies in cervical cancer () -  Oct 1, 2021 - Abstract #ESGO2021ESGO_431;    
    View this table: View inline View popup Download powerpoint Abstract 143 Table 1 Five examples of repurposing candidates for cervical cancer Conclusion* This study has identified potential candidates that are worth evaluating in cervical cancer. Although many drugs warrant additional preclinical and clinical investigation, we are exploring the possibility of conducting international collaborative multi-arm trials with one or several of these drugs.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Augmented antibody-based anti-cancer therapeutics boost neutrophil cytotoxicity. (Pubmed Central) -  Oct 1, 2021   
    Importantly, neutrophils of colorectal cancer patients effectively eliminated tumor cells in the presence of anti-epidermal growth factor receptor (EGFR) TrisomAb, but were less efficient in mediating killing in the presence of IgG α-EGFR mAb (cetuximab). The clinical application of TrisomAb may provide high potential alternatives for cancer patients that do not benefit from current IgG mAb therapy.
  • ||||||||||  subasumstat (TAK-981) / Takeda
    Trial primary completion date:  Intratumoral Microdosing of TAK-981 in Head and Neck Cancer (clinicaltrials.gov) -  Sep 26, 2021   
    P1,  N=12, Recruiting, 
    These data support the hypothesis that the combination of cetuximab with PI3K/Akt pathway inhibition might be a promising novel therapeutic strategy to overcome acquired cetuximab resistance in HNSCC patients. Trial primary completion date: Jun 2021 --> Nov 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Red Meat: An Unusual Allergy With Unique Anesthetic Considerations (Exhibit Hall) -  Sep 25, 2021 - Abstract #ASA2021ASA_4979;    
    In the mid-2000s, several patients in the Southeastern United States developed hypersensitivity reactions to cetuximab and red meat...Several medications administered in the perioperative period have ingredients that may contain alpha-gal. This case report raises awareness of the unique anesthetic considerations that are required of a patient with alpha-gal allergy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Reimbursement, Journal, HEOR, Medicare:  Comparative cost analysis between definitive radiotherapy and transoral surgery for oropharyngeal squamous cell carcinoma: A SEER-Medicare analysis. (Pubmed Central) -  Sep 24, 2021   
    Hence, both AS-2MPA-ALA-Cet based PDT and AS-2MPA-ALA-Cet-5FU based chemo/PDT combination therapy coupled with strong NIR tracking of the nanoparticles demonstrate an exceptional therapeutic effect on CRC cells and excellent potential for synergistic multistage tumour targeting therapy. In this population of elderly patients, transoral surgery was generally associated with less expensive treatment, with the addition of chemotherapy serving as the main driver of increased cost.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  External validation of nodal failure prediction models including radiomics in head and neck cancer. (Pubmed Central) -  Sep 24, 2021   
    In this population of elderly patients, transoral surgery was generally associated with less expensive treatment, with the addition of chemotherapy serving as the main driver of increased cost. The combined model including clinical and radiomic features was externally validated and proved useful to predict nodal failures and could be helpful to guide treatment choices before and after curative radiation treatment for node positive HNSCC patients.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial initiation date, Metastases:  Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy (clinicaltrials.gov) -  Sep 24, 2021   
    P=N/A,  N=51, Not yet recruiting, 
    The combined model including clinical and radiomic features was externally validated and proved useful to predict nodal failures and could be helpful to guide treatment choices before and after curative radiation treatment for node positive HNSCC patients. Initiation date: Jun 2021 --> Oct 2021